Sangamo Therapeutics (SGMO)
(Real Time Quote from BATS)
$0.55 USD
-0.01 (-1.19%)
Updated Jun 14, 2024 11:05 AM ET
3-Hold of 5 3
F Value C Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Sangamo Therapeutics, Inc. [SGMO]
Reports for Purchase
Showing records 1 - 20 ( 321 total )
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Unveils Potential Best-in-Class CNS-Targeting Capsid as Pipeline Expansion Takes Shape
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q4/FY23: Focus Remains on Advancing the Neurology Programs Toward the Clinic
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Novel AAV Capsid Breakthrough May Unlock Value in Multiple Neurology Programs; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Paving the Way for Potential Partnerships w/ ST-920 Regulatory STAAR Updates
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Potential Faster Path to Approval Makes Fabry Disease Program More Attractive For a Potential Partner
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Gene Therapy Program in Fabry Disease Shows Promising Results in Interim Phase 1/2 Readout; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
New Preclinical Data on CNS-Targeting Capsid Expected in 1Q24; IND on Nav1.7 Program on Track for 2H24; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Results; Announces Restructuring; Shifts to Neurology, Epigenetic Regulation, and AAV Delivery; Moderating PT to $3
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q3: Focus Shifts to Neuro Genomic Medicines; Restructuring Extends Runway
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Neurology Epigenetic Regulation and CARTreg Pipeline Data Shine at ESGCT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Results; Fabry Program Advancing to Phase 3; CAR Treg Data Expected 4Q23; Preclinical Pipeline on Track; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Update on the Path to Ph3 for ST-920/Fabry; Pipeline Progress; Q2:23 Financials
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology- Initial Takeaways - Days 1 and 2 of ASGCT 2023; Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q23 Results; Announces Restructuring; Fabry and CAR-Treg Programs Advancing; Unveils Neuro Programs; PT Down to $5
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P